Wall Street isn’t convinced the Ozempic maker has a promising path back to sustainable growth as competition from Eli Lilly intensifies.
Novo Nordisk’s raised forecast fails to change the debate over its obesity business
Related Posts
Building a secure auth code flow setup using AgentCore Gateway with MCP clients
In modern development workflows, developers increasingly rely on agentic coding assistants such as Kiro Integrated Development Environment (IDE) to interact…
United Arab Emirates leaving OPEC, effective May 1
The UAE said it decided leaving OPEC was in its national interest after reviewing its production policy and capacity.
UCSD Researchers Propose a General Variational Inference-based Framework (MCD) to Infer the Underlying Causal Models as well as the Mixing Probability of Each Sample
Researchers are struggling with the challenge of causal discovery in heterogeneous time-series data, where a single causal model cannot capture…